Feifei Xu

2.2k total citations · 1 hit paper
76 papers, 1.8k citations indexed

About

Feifei Xu is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Feifei Xu has authored 76 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Molecular Biology, 16 papers in Oncology and 14 papers in Cell Biology. Recurrent topics in Feifei Xu's work include Glycosylation and Glycoproteins Research (12 papers), Advanced Proteomics Techniques and Applications (10 papers) and Endoplasmic Reticulum Stress and Disease (8 papers). Feifei Xu is often cited by papers focused on Glycosylation and Glycoproteins Research (12 papers), Advanced Proteomics Techniques and Applications (10 papers) and Endoplasmic Reticulum Stress and Disease (8 papers). Feifei Xu collaborates with scholars based in China, United States and Philippines. Feifei Xu's co-authors include Yun Chen, Xiaojun Xia, Zining Wang, Xiaojuan Wang, Hongxia Zhang, Ting Yang, Peng Huang, Mengyun Li, Ting Yang and Yuan Sheng and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Clinical Investigation.

In The Last Decade

Feifei Xu

73 papers receiving 1.8k citations

Hit Papers

Delivery of mRNA vaccine with a lipid-like material poten... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling
    2021 213 citations Hongxia Zhang, Xiaojuan Wang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Feifei Xu China 24 1.2k 395 362 352 157 76 1.8k
Vinay Tergaonkar Singapore 22 1.5k 1.3× 356 0.9× 572 1.6× 537 1.5× 102 0.6× 31 2.4k
Lacey E. Dobrolecki United States 21 1.4k 1.2× 405 1.0× 891 2.5× 412 1.2× 159 1.0× 53 2.3k
Raymond E. Moellering United States 20 2.1k 1.8× 147 0.4× 448 1.2× 344 1.0× 101 0.6× 40 2.7k
Xiaonan Zhang Sweden 21 1.2k 1.0× 224 0.6× 475 1.3× 383 1.1× 120 0.8× 65 1.9k
Sejal Vyas United States 7 1.3k 1.2× 204 0.5× 425 1.2× 563 1.6× 162 1.0× 9 1.9k
Melissa Millard United States 14 1.1k 1.0× 151 0.4× 298 0.8× 228 0.6× 151 1.0× 18 1.9k
Jiyeon Kim United States 12 1.3k 1.2× 173 0.4× 332 0.9× 906 2.6× 104 0.7× 19 2.1k
Sarah J. Storr United Kingdom 22 1.2k 1.1× 267 0.7× 378 1.0× 283 0.8× 59 0.4× 56 1.8k
Ulrike Sattler Germany 15 1.4k 1.2× 167 0.4× 350 1.0× 884 2.5× 130 0.8× 20 2.0k
Takumi Shiraishi Japan 22 1.4k 1.2× 373 0.9× 390 1.1× 426 1.2× 52 0.3× 94 2.1k

Countries citing papers authored by Feifei Xu

Since Specialization
Citations

This map shows the geographic impact of Feifei Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feifei Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feifei Xu more than expected).

Fields of papers citing papers by Feifei Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feifei Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feifei Xu. The network helps show where Feifei Xu may publish in the future.

Co-authorship network of co-authors of Feifei Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Feifei Xu. A scholar is included among the top collaborators of Feifei Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feifei Xu. Feifei Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zhang, Yuanyuan, et al.. (2023). Nanoproteomics deciphers the prognostic value of EGFR family proteins-based liquid biopsy. Analytical Biochemistry. 671. 115133–115133. 1 indexed citations
3.
Zhang, Wenjun, Feifei Xu, Yao Jiang, et al.. (2023). Single-cell metabolic fingerprints discover a cluster of circulating tumor cells with distinct metastatic potential. Nature Communications. 14(1). 2485–2485. 34 indexed citations
4.
Wang, Zhongcheng, et al.. (2023). Simultaneous quantification of multiple single nucleotide variants in PIK3CA ctDNA using mass-tagged LCR probe sets. Talanta. 258. 124426–124426. 6 indexed citations
5.
Xu, Feifei, Zining Wang, Hongxia Zhang, et al.. (2021). Mevalonate Blockade in Cancer Cells Triggers CLEC9A+ Dendritic Cell-Mediated Antitumor Immunity. Cancer Research. 81(17). 4514–4528. 16 indexed citations
6.
Xu, Mengying, et al.. (2021). Simultaneous and quantitative monitoring transcription factors in human embryonic stem cell differentiation using mass spectrometry–based targeted proteomics. Analytical and Bioanalytical Chemistry. 413(8). 2081–2089. 1 indexed citations
7.
Wang, Tianjiao, Lu Zhang, Bowen Liu, et al.. (2019). Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma. EBioMedicine. 45. 168–180. 89 indexed citations
8.
Wang, Zining, Jiemin Chen, Jie Hu, et al.. (2019). cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity. Journal of Clinical Investigation. 129(11). 4850–4862. 185 indexed citations
9.
10.
11.
Yang, Ting, Feifei Xu, Yuan Sheng, Wen Zhang, & Yun Chen. (2016). A targeted proteomics approach to the quantitative analysis of ERK/Bcl-2-mediated anti-apoptosis and multi-drug resistance in breast cancer. Analytical and Bioanalytical Chemistry. 408(26). 7491–7503. 38 indexed citations
12.
13.
Xu, Feifei, Fengliang Wang, Ting Yang, et al.. (2014). Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells. Cancer Cell International. 14(1). 142–142. 74 indexed citations
14.
Xu, Feifei, Ting Yang, Danjun Fang, Qingqing Xu, & Yun Chen. (2014). An investigation of heat shock protein 27 and P-glycoprotein mediated multi-drug resistance in breast cancer using liquid chromatography-tandem mass spectrometry-based targeted proteomics. Journal of Proteomics. 108. 188–197. 27 indexed citations
15.
16.
Kong, Xiang-Zhen, Rong‐Hua Yin, Hongmei Ning, et al.. (2014). Effects of THAP11 on Erythroid Differentiation and Megakaryocytic Differentiation of K562 Cells. PLoS ONE. 9(3). e91557–e91557. 9 indexed citations
17.
Xu, Jinhui, Yuan Sheng, Feifei Xu, Ying Yu, & Yun Chen. (2013). Quantitative subcellular study of transferrin receptor-targeted doxorubicin and its metabolite in human breast cancer cells. European Journal of Drug Metabolism and Pharmacokinetics. 39(4). 301–310. 3 indexed citations
18.
19.
Xu, Feifei. (2007). Relative Entropy and Its Coefficient of Rough Fuzzy Sets. Journal of Tongji University. 1 indexed citations
20.
Liu, Xiuhua, et al.. (2005). Role of myofibrillogenesis regulator-1 in myocardial hypertrophy. American Journal of Physiology-Heart and Circulatory Physiology. 290(1). H279–H285. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vinay Tergaonkar Breakdown of academic impact, for papers by Lacey E. Dobrolecki Breakdown of academic impact, for papers by Raymond E. Moellering Breakdown of academic impact, for papers by Xiaonan Zhang Breakdown of academic impact, for papers by Sejal Vyas Breakdown of academic impact, for papers by Melissa Millard Breakdown of academic impact, for papers by Jiyeon Kim Breakdown of academic impact, for papers by Sarah J. Storr Breakdown of academic impact, for papers by Ulrike Sattler Breakdown of academic impact, for papers by Takumi Shiraishi
Rankless by CCL
2026